Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq:FHTX) announced management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The company, a clinical-stage biotechnology firm focused on oncology and abnormal gene expression, will join a fireside chat and hold one-on-one investor meetings.
The fireside chat is scheduled for Tuesday, June 9, 2026, at 1:20 p.m. EDT, featuring President and CEO Adrian Gottschalk. A webcast will be available in the Investors section of Foghorn’s website under “Events & Presentations” and remain accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – FHTX
In the Jun 5 session, FHTX declined 0.27%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Investor conferences | Neutral | -2.1% | Announcement of participation in three May 2026 investor conferences. |
| May 07 | Earnings update | Positive | -10.3% | Q1 2026 financials and pipeline update with cash runway into 1H 2028. |
| Apr 21 | Preclinical data | Positive | +3.6% | New AACR 2026 preclinical data for FHD-909 and multiple degrader programs. |
| Apr 09 | Data preview | Positive | -2.0% | Planned AACR 2026 presentations for FHD-909 and CBP, EP300, ARID1B programs. |
| Mar 11 | Financial outlook | Positive | -12.9% | 2025 financial update and 2026 strategic outlook with collaboration revenue and cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw negative price reactions, even to seemingly positive pipeline and financial updates, with only one of the last five events showing a positive 24-hour move.
Over the last few months, FHTX has highlighted steady oncology pipeline progress and financing strength. Updates on FHD-909 and degrader programs at the AACR meeting on Apr 21, 2026 coincided with a +3.61% move, but broader financial and strategic updates on Mar 11, 2026 and Q1 results on May 7, 2026 were followed by declines of -12.92% and -10.26%. Conference participation announcements, like those in May 2026, also saw modest pressure. Today’s Goldman Sachs conference participation fits this pattern of ongoing investor outreach amid a challenged share price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Fireside Chat: Tuesday, June 9, 2026, at 1:20 p.m. EDT
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Registration link: Register here
- Management will also participate in one-on-one meetings
A webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors section of the Company’s website here and will be available for 90 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
